Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome
NCT ID: NCT01660061
Last Updated: 2015-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2011-07-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
NCT05646394
Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome
NCT05195372
Use of Warfarin After the First Trimester in Pregnant Women With APS
NCT02303171
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
NCT01722786
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
NCT00878137
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective of this study is to determine the prevalence of interfering antiphospholipid antibodies. The intensity of anticoagulant therapy was assessed by measuring the INR using different thromboplastins and the CoaguChek system for INR self-assessment. Test results were compared to measurements of the phospholipid-independent chromogenic factor X.
The second objective of this study is to evaluate the incidence of recurrent thrombotic events during 1-year follow-up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
APS patients
Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
No interventions assigned to this group
Controls
Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johann Wolfgang Goethe University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Birgit Linnemann
Priv.-Doz. Dr. Birgit Linnemann
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Birgit Linnemann, MD
Role: PRINCIPAL_INVESTIGATOR
Goethe University Hospital, Division of Vascular Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Goethe University Hospital
Frankfurt am Main, Hesse, Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this study: Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EV 77/11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.